Medicines advice

Search Filters

Know what you're looking for?

Submission type

British National Formulary - Chapter

Pharmaceutical company

From

To

Advice

Accepted Not recommended Restricted Superseded Withdrawn Interim acceptance

Process

End of life/orphan Ultra orphan

Additional Details

Patient Access Scheme

Advanced Search

SMC ID	Date	Medicine	Submission Type	Indication
SMC2865	08/09/2025	encorafenib (Braftovi®)	Non submission	In combination with binimetinib for the treatment of adult patients with advanced non-small cell lung cancer with a BRAF V600E mutation.
SMC2238	10/02/2020	encorafenib (Braftovi)	Resubmission	In combination with binimetinib for the treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600 mutation.

No medicines have been found.